Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024

Anne J Huiberts; Christina E Hoeve; Brechje de Gier; Jeroen Cremer; Bas van der Veer; Hester E de Melker; Janneke Hhm van de Wijgert; Susan van den Hof; Dirk Eggink; Mirjam J Knol

doi:10.2807/1560-7917.ES.2024.29.10.2400109

Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024

Anne J Huiberts
, Christina E Hoeve
, Brechje de Gier
, Jeroen Cremer
, Bas van der Veer
, Hester E de Melker
, Janneke Hhm van de Wijgert
, Susan van den Hof
, Dirk Eggink
, Mirjam J Knol^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

10 Downloads (Pure)

Abstract

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23-55) in 18-59-year-olds and 50% (95% CI: 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8-2.6).

Original language	English
Article number	e2400109
Journal	Eurosurveillance
Volume	29
Issue number	10
DOIs	https://doi.org/10.2807/1560-7917.ES.2024.29.10.2400109
Publication status	Published - 7 Mar 2024

Access to Document

10.2807/1560-7917.ES.2024.29.10.2400109Licence: CC BY

eurosurv-29-10-2Final published version, 259 KBLicence: CC BY

Cite this

Huiberts, A. J., Hoeve, C. E., de Gier, B., Cremer, J., van der Veer, B., de Melker, H. E., van de Wijgert, J. H., van den Hof, S., Eggink, D., & Knol, M. J. (2024). Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024. Eurosurveillance, 29(10), Article e2400109. https://doi.org/10.2807/1560-7917.ES.2024.29.10.2400109

@article{c0239fbe818f4cc2bb3965d407177906,

title = "Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024",

abstract = "We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41\% (95\% CI: 23-55) in 18-59-year-olds and 50\% (95\% CI: 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95\% CI:1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95\% CI:0.8-2.6).",

author = "Huiberts, \{Anne J\} and Hoeve, \{Christina E\} and \{de Gier\}, Brechje and Jeroen Cremer and \{van der Veer\}, Bas and \{de Melker\}, \{Hester E\} and \{van de Wijgert\}, \{Janneke Hhm\} and \{van den Hof\}, Susan and Dirk Eggink and Knol, \{Mirjam J\}",

year = "2024",

month = mar,

day = "7",

doi = "10.2807/1560-7917.ES.2024.29.10.2400109",

language = "English",

volume = "29",

journal = "Eurosurveillance",

issn = "1560-7917",

publisher = "Centre Europeen pour la Surveillance Epidemiologique du SIDA",

number = "10",

}

Huiberts, AJ, Hoeve, CE, de Gier, B, Cremer, J, van der Veer, B, de Melker, HE, van de Wijgert, JH, van den Hof, S, Eggink, D & Knol, MJ 2024, 'Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024', Eurosurveillance, vol. 29, no. 10, e2400109. https://doi.org/10.2807/1560-7917.ES.2024.29.10.2400109

Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024. / Huiberts, Anne J; Hoeve, Christina E; de Gier, Brechje et al.
In: Eurosurveillance, Vol. 29, No. 10, e2400109, 07.03.2024.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024

AU - Huiberts, Anne J

AU - Hoeve, Christina E

AU - de Gier, Brechje

AU - Cremer, Jeroen

AU - van der Veer, Bas

AU - de Melker, Hester E

AU - van de Wijgert, Janneke Hhm

AU - van den Hof, Susan

AU - Eggink, Dirk

AU - Knol, Mirjam J

PY - 2024/3/7

Y1 - 2024/3/7

N2 - We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23-55) in 18-59-year-olds and 50% (95% CI: 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8-2.6).

AB - We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23-55) in 18-59-year-olds and 50% (95% CI: 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8-2.6).

UR - https://www.scopus.com/pages/publications/85187515467

U2 - 10.2807/1560-7917.ES.2024.29.10.2400109

DO - 10.2807/1560-7917.ES.2024.29.10.2400109

M3 - Article

C2 - 38456217

SN - 1560-7917

VL - 29

JO - Eurosurveillance

JF - Eurosurveillance

IS - 10

M1 - e2400109

ER -

Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024

Abstract

Access to Document

Other files and links

Fingerprint

Cite this